The Exacerbation of Chronic Kidney Disease due to Uncontrolled Vitamin D Supplementation- Case Report

Special Article: Vitamins

Int J Nutr Sci. 2024; 9(1): 1080.

The Exacerbation of Chronic Kidney Disease due to Uncontrolled Vitamin D Supplementation- Case Report

Miroslaw Snit, MD, PhD¹; Dariusz Szczyra, MD¹*; Paulina Ziólkowska²; Michalina Strzedulla, MD, PhD²; Janusz Gumprecht¹

¹Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Poland

²Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland

*Corresponding author: Dariusz Szczyra, MD Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 15 Poniatowskiego Str., 40-055 Katowice, Poland. Email: dszczyra@sum.edu.pl.

Received: December 07, 2023 Accepted: January 06, 2024 Published: January 13, 2024

Abstract

Vitamin D plays a vital role in the proper functioning of the human body. It is involved in the regulation of calcium-phosphate metabolism. Currently, the problem of vitamin D deficiency is well-known. Additional oral supplementation is widespread, furthermore the number of cases of vitamin D overdose is increasing. A strong indication of toxicity is hypercalcemia. Excessive supplementation may lead to calcium deposits in tissues and organs and finally lead to damage and conduction disorders. The presented patient used high doses (over 10 000 units per day) of vitamin D for a few months. He was admitted to the hospital with an increased serum creatinine level of 352 μmol/l. The progressive chronic kidney disease was diagnosed, and the replacement renal therapy was considered. After 13 days of treatment, the patient had a good clinical response with the gradual normalization of kidney function and decreased vitamin D and its metabolites serum concentrations. In case of excessive vitamin D intake and symptoms of toxicity, it is essential to monitor the patient for at least 6 months because of the slow release of vitamin D from fat deposits.

Keywords: Vitamin D; Vitamin D toxicity; Vitamin D supplementation; Overdose; Kidney failure; Hypercalcemia

Introduction

Vitamin D is a well-known representative of a fat-soluble vitamin group. It is released, absorbed and transported with dietary fat. The common name “vitamin D” includes, in fact, two significant compounds - ergocalciferol (also known as vitamin D2) and cholecalciferol (the other name is vitamin D3). Vitamin D plays a vital role in the proper functioning of the human body, especially in regulating calcium and phosphate metabolism [1]. Sun exposure and oral intake are the two main sources of the following vitamin. The first includes the natural synthesis of cholecalciferol in the lower layers of the epidermis induced by ultraviolet radiation, whereas oral intake involves diet and conscious supplementation. Vitamin D occurs naturally only in a few comestible products, such as fish, meat, liver and eggs. Consequently, supplementation is an essential issue as vitamin D deficiency is a global problem. More than one billion people worldwide are estimated to suffer from vitamin D deficiency [2]. Due to this, nowadays, a wide range of different supplements containing vitamin D are widely available. However, many of them have an unregulated composition. Moreover, the guidance for their safe application is often insufficient. As a result of both these factors, there is an increased number of cases with excessive supplementation and possible symptoms of vitamin D like apathy, vomiting, abdominal pain, polyuria, polydipsia and dehydration [3, 4]. Treatment includes limiting calcium intake, discontinuing vitamin supplementation, intravenous hydration and intake of the drugs decreasing serum calcium level.

Pathomechanism of Vitamin D Toxicity

In 2008, 3 main hypotheses were proposed regarding the mechanism of Vitamin D Toxicity (VDT). All three involve increased concentrations of a vitamin D metabolite reaching the Vitamin D Receptor (VDR) in the nucleus of target cells and causing gene overexpression: 1. Toxicity is mediated by increased serum concentrations of the active hormonal form, 1,25(OH) 2 D, leading to increased intracellular concentration. 2. 1,25(OH) 2D has a low affinity for Vitamin D Binding Protein (VDBP) and a high affinity for VDR, making it an important ligand for accessing the transcriptional signal transduction machinery. In hypervitaminosis D, the concentrations of various vitamin D metabolites, especially 25(OH)D, are significantly increased, saturating the binding capacity of VDBP, which allows other vitamin D metabolites to enter the cell nucleus. Of the various vitamin D metabolites, 25(OH)D at higher concentrations (a dose-dependent effect) has the strongest affinity for the VDR, so a particular metabolite at elevated serum concentrations stimulates transcription. 3. Ingestion of vitamin D raises the concentration of vitamin D itself and increases the concentration of many other vitamin D metabolites, especially 25(OH)D. In vitamin D hypervitaminosis, the concentrations of vitamin D metabolites, such as vitamin D, 25(OH)D, 24,25(OH) 2 D, 25,26(OH) 2 D and 25(OH)D-26,23 -lactone, increase significantly Abnormally elevated concentrations of vitamin D metabolites exceed the binding capacity of VDBP and cause the release of free 1,25(OH) 2 D; the latter active metabolite enters target cells by diffusion and acts through the vitamin D receptor [14,17].

Guidelines for Vitamin D Supplementation in Poland and Europe

Poland and Central Europe: The initiation of vitamin D supplementation should begin with the determination of vitamin D requirements, the best determinant of which is the serum concentration of the liver metabolite 25(OH)D. According to the Central European guidelines, suboptimal supply is assumed to occur at a serum 25(OH)D concentration of 20-30 ng/ml (50-75 nmol/l). In contrast, maintaining a concentration of 30-50 ng/ml (75-125 nmol/l) was considered to ensure the pleiotropic effect of vitamin D. The finding of higher serum concentrations (above 100 ng/ml, i.e., above 250 nmol/l) may indicate improper supplementation and is an indication for total discontinuation of treatment [21].

According to the above recommendations, 20 to 50 ug/day of vitamin D should be used. [22]

In 2021. The Chief Sanitary Inspectorate (GIS) in Poland regulated the maximum doses of vitamin D in dietary supplements. These are, respectively:

- 2,000 IU (50 μg) for dietary supplements intended for the healthy adult population up to age 75 (01/2021);

- 4,000 IU (100 μg) for dietary supplements intended exclusively for the healthy population of adults over 75 years of age. (01/2021).

Europe: In western, southern European and Scandinavian countries vitamin D supplementation is recommended after the prior determination of serum concentrations of the hepatic metabolite 25(OH)D in 2019. Lips et al., in their publication based on country-specific data, reported that vitamin D requirements for adults (including older adults ranged from 0 to 20 ug/day. [22]

Case Report

67-years old male was admitted to the hospital for diagnosis of rapidly progressive chronic kidney disease (visualized incidentally during laboratory tests performed by the GP who referred the patient to the Nephrology consultation) with unclear aetiology of kidney failure as well as for consideration of the possible need for renal replacement therapy. Previous blood tests revealed increased serum creatinine levels and hypercalcemia. The patient was diagnosed with hypertension, hypertriglyceridemia, liver steatosis, left acoustic neuroma and lichen sclerosis. At the time of admission, he did not report any symptoms and signs. The patient stated that he had been using high doses of vitamin D (over 10 000 units per day for a few months) as the supplemental therapy. The patient was unaware of the threats, and thought he was using the correct dosage. No alcohol use, no herbal agents and no suspected drug use were reported. Physical examination did not reveal any relevant abnormalities. The patient appeared alert, oriented and cooperative. Auscultation showed normal heart sounds as well as normal symmetrical vesicular sounds. No abdominal findings were referred. Vital signs of the patient were also in the normal ranges with 36.6oC body temperature, 75/min. heart rate and 96% blood oxygen saturation without additional oxygen therapy, arterial blood pressure was slightly increased 140/80.

Laboratory tests were performed during the admission. The following results were obtained: serum creatinine level: 352 μmol/l (normal range: 62-106 μmol/l), eGFR: 16.03 ml/min/1.73m2 (normal value >60 ml/min/1.73m2), total vitamin D >100 ng/ml, vitamin D metabolite 25(OH) > 308 ng/ml (concentration >100 ng/ml is considered potentially toxic), vitamin D metabolite 1.25(OH)2: 585 pg/ml (normal range: 25.00-86.50 pg/ml), parathormone: 7.76 pg/ml (normal range: 10-60 pg/ml), HCT: 26,1% (normal range: 42-52%), RBC: 3.21 x106/μl (normal range: 4.7-6 x106/μl), HGB: 9.7 g/dl (normal range: 13.5-17 g/dl), triglycerides: 1.94 mmol/l (normal range <1.7 mmol/l). The arterial blood gases analysis was normal. There were also some electrolyte disturbances such as hyponatremia: 120 mmol/l (normal range: 135-145 mmol/l), hyperkalemia: 5.55 mmol/l (normal range: 3.5-5.1 mmol/l) as well as hypercalcemia - the total calcium level was 3.62 mmol/l (normal range: 2.12–2.62 mmol/l). The serum protein immunofixation was performed and did not reveal the monoclonal gammapathy. The urinalysis also did not show any abnormalities.

The performed12-lead electrocardiography record presented the sinus rhythm with a frequency of 70/min. as well as the left anterior hemiblock, probably caused by high calcium concentration.

The patient underwent a series of medical imaging to extend the diagnostics of the reasons for kidney failure (figure 1, 2). Some of them were interpreted as normal and showed no signs of osteolysis, such as the skull and pelvic radiographs. The chest X-ray reported only minor abnormalities in the lung’s stroma. During the hospitalization, abdominal ultrasonography was also performed revealing slightly higher echogenicity of the liver, pointing to steatosis, significantly elevated echogenicity of the renal cortex and a small cortical cyst (6 mm) in the left kidney.

Because of unclear aetiology of the patient’s symptoms, the renal biopsy was under consideration, however, patient’s informed consent could not be obtained. For this reason, the biopsy was abandoned.

During hospitalization, intravenous fluid therapy was implemented. It consisted of 500 ml 0.9% NaCl with addition of 20 ml of 10% NaCl (on the first day of hospitalization for severe hyponatremia). The aim of that therapy included the protective impact on renal function, the minimalization of hyponatremia and the treatment of hypercalcemia. A good response was obtained progressively (table 1). The treatment also involved the administration of 2000 ml 0.9 % NaCl, Furosemidum 2 x 40 mg i.v., intravenous bisphosphonates (Pamindronate disodium 90 mg/ 500 ml 0,9% NaCl, 3 doses from the 7th to 9th day) and glucocorticosteroids per os (Metyloprednisolone16 mg- 8 mg from 8th day). The aim was to reduce the calcium concentration. The impaired kidney function subsequently led to anaemia, with haemoglobin concentration decreased to 7.1 g/dl. For that reason, blood transfusion was necessary. During hospitalization, the patient did not report symptoms of gastrointestinal bleeding only persistent constipation. After laxative infusion, blood-colored stool was observed (1 episode). He did not agree to gastrointestinal endoscopic diagnostics, with the approval of the patient (initially, he also did not agree), he obtained 4 units of packed red blood cells after crossmatch.